Gender-specific associations between apolipoprotein A1 and arterial stiffness in patients with nonalcoholic fatty liver disease

Xulong Sun, Equal first author, 1, 2, Ruifang Chen, Equal first author, 1, Guangyu Yan, 1, Zhiheng Chen, 3, Hong Yuan, 1, Wei Huang, Correspond, 1, Yao Lu, Correspond, 1, 4

1 Clinical Research Center, The Third Xiangya Hospital of Central South University, Changsha, China
2 Department of General Surgery, The Third Xiangya Hospital of Central South University, Changsha, China
3 Health Management Center, The Third Xiangya Hospital of Central South University, Changsha, China
4 Department of Life Science and Medicine, King’s College London, London, United Kingdom

Corresponding Authors: Wei Huang, Yao Lu
Email address: 118312057@csu.edu.cn, yao.lu@kcl.ac.uk

Background: Lipid metabolism factors may play an important role in the progression of Nonalcoholic fatty liver disease (NAFLD) and its related cardiovascular dysfunctions. The study aims to assess whether Apolipoprotein A-1 (ApoA1) was associated with vascular stiffness in NAFLD patients.

Methods: From 2012-2013, we included 2,295 non-alcohol users with fatty liver disease (1,306 male patients) and completely excluded subjects who drank any alcohol ever to eliminate the effect of alcohol intake. The serum ApoA1 levels and the brachial-ankle pulse wave velocity (baPWV) were measured.

Results: Male’s baPWV is much higher than female patients (1412.79 cm/s VS 1358.69 cm/s, P<0.001). ApoA1 level was positively associated with baPWV (Odd Ratio(OR), 4.18; 95% confidence interval (CI), 1.16-15.1, P<0.05) in patients with AST/ALT<1 and (OR, 4.70; 95% CI, 1.36-16.23, P<0.05) in patients with AST/ALT≥1 respectively. Only male’s arterial stiffness is associated with ApoA1 (OR, 3.96; 95% CI, 1.29, 12.30, P<0.05) in logistics regression models adjusted for age, gender, body mass index(BMI), education attainment, physical activity, smoking, history of hypertension and high-density lipoprotein(HDL).The relationship between ApoA1 and baPWV in male NAFLD patients remained significant (Confidence, 156.42; 95% CI, 49.34-263.50. P<0.05) in the fully adjusted linear regression model.

Conclusion: The serum ApoA1 was associated with arterial stiffness in male NAFLD patients. Increased ApoA1 level should be considered as an independent risk factor for arterial stiffness in male NAFLD patients, suggesting that NAFLD may alter arterial stiffness by “ApoA1-related” mechanism in men.
Gender-specific associations between Apolipoprotein A1 and arterial stiffness in patients with Nonalcoholic Fatty Liver Disease

Xulong Sun 1,2*, Ruifang Chen1*, Guangyu Yan1, Zhiheng Chen3, Hong Yuan1, Wei Huang1, Yao Lu1,4

1 Clinical Research Center, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
2 Department of General Surgery, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
3 Health Management Center, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
4 Department of Life Science and Medicine, King’s College London, London, United Kingdom

*These authors contributed equally.

Corresponding Author:
Yao Lu1,4
the Third Xiangya Hospital of Central South University, 138 Tongzipo Road, Changsha, Hunan, 410013, China.
Email address: yao.lu@kcl.ac.uk

Wei Huang1
the Third Xiangya Hospital of Central South University, 138 Tongzipo Road, Changsha, Hunan, 410013, China.
Email address: 118312057@csu.edu.cn
Abstract

Background: Lipid metabolism factors may play an important role in the progression of Nonalcoholic fatty liver disease (NAFLD) and its related cardiovascular dysfunctions. The study aims to assess whether Apolipoprotein A-I (ApoA1) was associated with vascular stiffness in NAFLD patients.

Methods: From 2012-2013, we included 2,295 non-alcohol users with fatty liver disease (1,306 male patients) and completely excluded subjects who drank any alcohol ever to eliminate the effect of alcohol intake. The serum ApoA1 levels and the brachial-ankle pulse wave velocity (baPWV) were measured.

Results: Male's baPWV is much higher than female patients (1412.79 cm/s VS 1358.69 cm/s, P<0.001). ApoA1 level was positively associated with baPWV (Odd Ratio(OR), 4.18; 95% confidence interval (CI), 1.16-15.1, P<0.05) in patients with AST/ALT<1 and (OR, 4.70; 95% CI, 1.36-16.23, P<0.05) in patients with AST/ALT ≥ 1 respectively. Only male’s arterial stiffness is associated with ApoA1 (OR, 3.96; 95% CI, 1.29, 12.30, P<0.05) in logistics regression models adjusted for age, gender, body mass index(BMI), education attainment, physical activity, smoking, history of hypertension and high-density lipoprotein(HDL).The relationship between ApoA1 and baPWV in male NAFLD patients remained significant (Confidence, 156.42; 95% CI, 49.34-263.50. P<0.05) in the fully adjusted linear regression model.

Conclusion: The serum ApoA1 was associated with arterial stiffness in male NAFLD patients. Increased ApoA1 level should be considered as an independent risk factor for arterial stiffness in male NAFLD patients, suggesting that NAFLD may alter arterial stiffness by “ApoA1-related” mechanism in men.
Introduction

Nonalcoholic fatty liver disease (NAFLD) is increasingly recognized as a major chronic liver disease not only in Western countries but also in Asia countries like China in which 15–30% of the general adult population suffers from NAFLD (Wong 2013). NAFLD, which is characterized by the accumulation of triglycerides in hepatocytes in the absence of excessive alcohol intake and considered as systemic consequence(Byrne & Targher 2015; Francque et al. 2016), has been confirmed to be associated with an increased risk of cardiovascular disease (CVD) and the incidence of cardiovascular events(De Alwis & Day 2008). There is substantial evidence that NAFLD is associated with increased coronary artery calcification, increased pulse wave velocity (PWV), increased coronary membrane thickness, endothelial dysfunction, all of which are established markers of CVD (Fan et al. 2016; Iannaccone et al. 2007; Vlachopoulos et al. 2010).

More specifically, evidence NAFLD begins with the aberrant accumulation of triglyceride in the liver, thus lipid metabolism disorders play an important role in the disease progression as well as its complications like vascular dysfunction and related CVD outcomes (Francque et al. 2016).

Therefore, it is vital to identify the potential risk or biomarkers for the prevalence of cardiovascular diseases and related complications like arterial stiffness and vascular dysfunction, especially in NAFLD patients.

PWV is a valuable tool for assessing arterial stiffness by measuring the pulse propagation time and the travel distance between the studied arterial site, which is associated to abnormal vascular tone, thickening of smooth muscle and changes in blood viscosity(Deloach & Townsend 2008; Kelly et al. 1989). Therefore, PWV is considered as a important marker of CVD events (Ba et al. 2013). Nevertheless, aortic stiffness modulation remains a strong target for therapeutic intervention, as it is the most powerful cardiovascular risk factor indeed a surrogate outcome rather than a risk factor.

Arterial stiffness could be progressive due to lipid metabolism (Fok & Cruickshank 2015).

Lipoprotein metabolism is usually thought to be associated with arterial changes, which will be of great interest in knowing how and to what extent arterial stiffness conditions are associated with CVD events in NAFLD patients (Sorokin & Kotani 2015). Patients with NAFLD often have imbalances in lipid metabolism resulting in elevated very low lipoprotein and decreased high-density lipoprotein (HDL) levels as well as low-density lipoprotein (LDL). Therefore, more lipid biomarkers should be identified to predict vascular dysfunctions. Recent studies forced on the effect HDL and LDL on arterial stiffness (Caldas et al. 2013; Gordon et al. 2013), but few concentrated on the protein components of these lipoproteins, especially in NAFLD patients.

Apolipoprotein A-1 (ApoA1) is the major protein component of HDL, which plays an essential role in lipid production and in an important modulator of processes associated with glucose intolerance and diet-induced NAFLD development (Castellani & Lusis 2001; Smith 2010).

Lower ApoA1 has been reported to be statistically significant associations with high-risk atherosclerosis (Zhao et al. 2014). Nevertheless, the relationship between ApoA1 and PWV remains unknown.
In this study, we addressed the question whether the serum ApoA1 concentration was associated with or was a risk factor for NAFLD. Whether ApoA1 was associated with arterial stiffness; and also the relationship between ApoA1 and PWV in NAFLD were examined.

**Materials & Methods**

People were recruited in the Health Management Center of The Third Xiangya Hospital from March 2012 to December 2013. The study was approved by the Institutional Review Board of Central South University (R18030) and informed oral consent was obtained from all subjects. Evidence including non-alcoholic users NAFLD and NAFLD is based on the following items:(1) The diffusion of near-field echoination in the hepatic region increases (stronger than that in the kidney and spleen) and the far field echo is gradual attenuated;(2) Intra-hepatic lacuna structure is not clear; (3) Mild to moderate hepatomegaly, with round and blunt border;(4) Color Doppler ultrasound shows a decrease or even difficulty in showing blood flow signals in the liver, but the distribution of blood flow is normal.If any one or more matches in items 1 and 2-4 are made, the NAFLD is diagnosed. Hepatic ultrasound is carried out blindly by trained ultrasoundists (De Zeng et al. 2008).

The exclusion criteria were as follows: 1) patients with hepatotoxic drug treatment; 2) history of heart failure, stroke, arteriosclerosis, and diabetes; 3) participants with hepatitis C virus (HCV), hepatitis B virus (HBV) and any chronic liver disease; 4) participants with other chronic diseases: human immunodeficiency virus (HIV), cancer and end-stage kidney disease; 5) incomplete data information.

**Clinical and laboratory assessments**

Anthropometric factors include height, weight, systolic blood pressure (SBP), diastolic blood pressure (DBP) and the brachial-ankle pulse wave velocity (baPWV). Body mass index (BMI) was calculated as weight (kg) divided by height squared (m$^2$). Weight and height were measured after participants had removed their shoes and heavy clothing. They were measured in meters using a scale from the G-TECH Company. Blood pressure measurements were done with a mercury sphygmomanometer with the participants in a chair using the right arm after 5 min in rest. The average value of three readings was accepted as SBP and DBP.

Serum HDL, LDL and ApoA1 were prepared from fasting blood samples, and the supernatant was collected and stored at $-20^\circ$C and $-80^\circ$C. The serum levels of HDL, LDL were determined by enzymatic methods and the Friedwald equation and ApoA1 was measured by an immunological turbidity testing. They were measured using a biochemical detector from the HITACHI Company (7600-020).

The definition of social behavior factors has also been reported in our previous study(Lu et al. 2015). Educational attainment is categorized as “< college graduation”, “college graduation” or “>college graduation”. Physical activity and smoking had different types in the standard questionnaires. Physical activity was categorized as “Never”, “Occasionally” or “Frequently (vigorous exercise at least three times per week).” Smoking was categorized as “Quit”, “Never”, “Occasionally” or “Frequently”. The diagnostic criteria of hypertension history were systolic or diastolic blood pressure $\geq 140$ or $\geq 90$mmHg.
baPWV measurement
The brachial-ankle pulse wave velocity values were assessed using an automatic, non-invasive vascular screening device Omron health medical (China) LTD, calculated as the distance travelled by the pulse wave divided by the time taken to travel the distance. The baPWV values were measured by the average of the left side baPWV and right side baPWV. The baPWV value is measured by the average of the baPWV on the left and the baPWV on the right. This is obtained by measuring blood pressure levels and pulsewaves in the arms and legs with four pneumatic pressure cuffs around the four limbs. Measurements were taken between 7:30 and 9:00 in the morning on the examination day. All the data was collected after the participants had 5 min of bed rest.

Since the reference value of baPWV up to 1400 cm/s was used as an indicator of the severity of arteriosclerosis vascular damage, increased arterial stiffness was defined as baPWV of 1400 cm/s or higher(Yamashina et al. 2003).

Statistical Analysis
Values for continuous variables are presented as mean ± SD. Comparisons between female NAFLD patients and male NAFLD patients were performed using Pearson’s Chi-square analysis for categorical variables and T-test for continuous variables. Multivariate logistic regression was used to assess the association between ApoA1 and baPWV totally and separately by gender. Linear regression analysis was used to determine the correlation between ApoA1 and baPWV in male NAFLD patients. The analysis was conducted after adjusted for age, gender, BMI, education, physical activity, smoking, history of hypertension, HDL and LDL level. As serum AST/ALT ratio is a good index to assess fibrosis advances. Patients can be divided into two groups by comparison of the ratio to 1. Adjusted odds ratio and 95% confidence intervals (CIs) were calculated. An odds ratio (OR) >1 was considered a risk factor, and an OR <1 was considered as a protective factor.

For exploratory purposes, the adjusted relationship between ApoA1 and the incidence of arterial stiffness was also assessed by a multivariate logistic regression model with restricted cubic splines. The relationships were depicted based on this model in which ApoA1 levels were categorized into 0.5 g/L increment from <1 to >3 g/L and were adjusted for age, gender, BMI, education, physical activity, smoking, history of hypertension, HDL and LDL level. Values of P <0.05 were considered statistically significant. All the data analyses and figure were performed using STATA software version 14.0.

Results
A total of 2,295 subjects (1,306 males) were enrolled the baseline characteristics of the study participants grouped by gender are shown in Table 1. The participants’ mean age was 48.47±10.22 years old, and the average BMI was 24.8±3.3 kg/m². The means of systolic and diastolic blood pressure were 124.65±16.54 and 78.13±11.35 mmHg. The average HDL and LDL were 1.58±0.4 mmol/L and 3±0.88 mmol/L. The means of ApoA1 and baPWV were 1.51±0.28 g/L and 1389.48±273.5 cm/s. There were significant differences in education attainment, smoking, and history of hypertension prevalence between male and female NAFLD patients (P<0.05).
Female NAFLD patients are older and had lower BMI, blood pressure, baPWV and predominantly had higher HDL and ApoA1 level (P<0.05, Table 1). The total prevalence of arterial stiffness is 41.56%, the prevalence for men is much higher than that for women (44.79% VS 35.39%, P<0.001) (Table 1). A multi-logistic regression analysis was performed to reveal the relationship between ApoA1 and baPWV among NAFLD patients with different genders. The results of three different models were displayed in Table 2. In model 1, after adjusted for age, gender, and BMI, only ApoA1 level in male NAFLD patients was significantly associated with baPWV (OR, 1.93; 95% CI, 1.22-3.05. P<0.001). In model 2 which adjusted for age, gender, BMI, education attainment, physical activity, smoking, and history of hypertension, the overall ApoA1 level in NAFLD patients was positively associated with baPWV (OR, 1.69; 95% CI, 1.08-2.66. P<0.05); ApoA1 level in male NAFLD patients was significantly associated with baPWV (OR, 2.80; 95% CI, 1.55-5.04. P<0.001). No statistically significant association was observed between female NAFLD patients’ ApoA1 level and baPWV. In model 3, adjusted for model 2 and HDL and LDL, the overall ApoA1 level in NAFLD patients was significantly associated with baPWV (OR, 4.46; 95% CI, 1.85-10.77. P<0.001); ApoA1 level in male NAFLD patients was significantly associated with baPWV (OR, 3.96; 95% CI, 1.29-12.30. P<0.05). No statistically significant association was observed between ApoA1 and baPWV in female patients (Table 2). In the subgroups divided by serum AST/ALT ratio, in model 1, only ApoA1 level in AST/ALT<1 subgroup was significantly associated with baPWV (OR, 1.88; 95% CI, 1.06-3.33. P<0.05). In model 3, the overall ApoA1 level in two subgroups was positively associated with baPWV, (OR, 4.18; 95% CI, 1.16-15.1. P<0.05) in AST/ALT<1 subgroup and (OR, 4.70; 95% CI, 1.36-16.23. P<0.05) in AST/ALT ≥1 subgroup respectively.

As shown in Table 3, the relationships between ApoA1 and baPWV in male NAFLD patients were analyzed by linear regression. In model 1, the relationship between ApoA1 and baPWV in male patients was found to be significant in univariate analysis (coefficient, 160.02; 95% CI, 107.37-212.66. P<0.001). In model 2, after adjusting for age, gender, BMI, education attainment, physical activity, smoking and history of hypertension, the relationship between ApoA1 and baPWV in male patients was statically significant (coefficient, 139.84; 95% CI, 83.97-195.68. P<0.001). In model 3, which adjusted for model 2 and HDL and LDL, the relationship between ApoA1 and baPWV in male NAFLD patients remained significant (coefficient, 156.42; 95% CI, 49.34-263.50. P<0.05). ApoA1 is associated with the incidence of arterial stiffness only in male NAFLD patients.

The relationship between ApoA1 and the incidence of arterial stiffness in male patients followed a J-shaped curve, with increased odds ratio at low and high ApoA1. In a multivariable logistic regression model, using ApoA1 as a covariate, adjusting for baseline covariates, the risk for the incidence of arterial stiffness increased with ApoA1 (Figure 1).

**Discussion**

The major finding of this study is that risk of arterial stiffness increased with increasing ApoA1
after adjusting for multi-confounders in NAFLD subjects. The relationship between arterial stiffness and ApoA1 was statistically significant only in male NAFLD population. The prevalence of NAFLD is likely to rise even further not only in western countries but also in developing countries as China. There is growing evidence that NAFLD must be considered an important independent risk factor for CVD(Ozturk et al. 2015). Longitudinal studies have shown that cardiovascular mortality is the most important cause of death in patients with NAFLD(Byrne et al. 2009). But the mechanisms by which NAFLD contributes to cardiovascular disease have not yet been fully clarified. In our current study based on a mean age of 48.7 years old population, the mean baPWV is 1389.48 ± 273.5 cm/s, which is even much higher (p < 0.001) than Chinese population with an equal age level (p=0.066) (mean value: 1340cm/s) (Zeng et al. 2016). NAFLD is associated with increased baPWV, thus it is of vital importance to identify the risk factors for arterial stiffness in this specific population.

Hepatic steatosis arises from an imbalance between triglyceride (TG) acquisition and removal. Many studies have demonstrated that hepatic TG accretion from increased dietary intake, repartitioning of TG from adipose tissue to the liver, or increased de novo lipogenesis result in hepatic steatosis(Berlanga et al. 2014; Cohen et al. 2011) [24,25]. ApoA1 is the major apolipoprotein in HDL, which plays an important role in fatty acid metabolism(Yanai et al. 2015), thus ApoA1 can influence NAFLD by regulating the accumulation of liver triglyceride intake in the diet(Choe et al. 2013). ApoA1 plays a central role in the process of reverse cholesterol transport (RCT), which has been thought to be the major mechanism of the antiatherogenic functions of HDL(Yancey et al. 2003). In animal models, increasing HDL-C levels did not affect the rates of RCT, and the rate of RCT achieved the maximum at the normal levels of HDL-C(Alam et al. 2001). While infusion of a smaller ApoA1 containing into mice was found to increase reverse cholesterol transport, and over-expression of ApoA1 was found to favor efflux of cholesterol(Alam et al. 2001). At the same time, the liver is the major producers of ApoA1 as well as the important location of reverse cholesterol transport(Timmins et al. 2005). Due to the limited studies on the relationship of ApoA1 and NAFLD, further research should be conducted to clarify other potential mechanisms by which ApoA1 could affect the pathologic processes of NAFLD.

According to previous studies, lower ApoA1 may have positive effect on atherosclerosis or high-risk plaque features(Zhao et al. 2014), which is exactly in contradiction to our results. As there are few publications focusing on the relationships between ApoA1 and PWV, unanimous conclusions couldn’t be drawn before we conducted more long-term large-scale clinical trials. In our study on NAFLD subjects, men had significantly higher level of baPWV levels and arterial stiffness than women, consistent with the results of some multicenter studies on the general population(Kim et al. 2014). Many factors, such as body size, biochemical properties of arteries, sex hormones, can lead to differences in arterial stiffness between male and female(Janner et al. 2010; Rossi et al. 2011; Segers et al. 2007). Some studies showed the distribution of ApoA1 differs between men and women, higher in women than in men (Csaszar et al. 1991; Valles et al. 2002). A study of 147576 Swedish males and females aimed at ApoA1
Distribution shown that the ApoA1 concentration was 10% lower than in females (1.36±0.22g/L VS 1.51±0.24g/L) (Jungner et al. 1998), which is consistent with the National Health and Nutrition Examination Survey III of the United States (Bachorik et al. 1997). Therefore, we investigated the relationships between arterial stiffness and ApoA1 in different gender group for the first time. Female NAFLD subjects’ serum ApoA1 level is much higher than Male’s (1.62 VS 1.42, P<0.05), which is exactly consistent with the results from other populations. The difference in ApoA1 level in different gender groups implied that sex hormones may play an important role in serum ApoA1 level. Both basic and bench research may be designed to test hypothesis and the internal mechanisms.

Limitation

Fatty liver was diagnosed by ultrasonography rather than liver biopsy pathology. Liver biopsy is the "gold standard" for defining fat accumulation, inflammation and fibrosis in liver, but it is not suitable as a screening method for population-based epidemiological studies due to the invasiveness of liver biopsy. Additionally, this current study only investigated the relationships on NAFLD patients in a cross-section research, to clarify the impact of ApoA1 on CVD risks, further longitudinal study should be performed. Despite these limitations, this study conducted a meaningful study of the relationship between ApoA1 and arterial stiffness in NAFLD subjects.

Conclusions

Unlike the protective effect of ApoA1 on atherosclerosis, the serum ApoA1 was associated with arterial stiffness in male NAFLD patients, suggesting that NAFLD may alter arterial stiffness by “ApoA1-related” mechanism in male NAFLD population.

Acknowledgements

We are very thankful the suggestions on our work from Prof. Cruickshank Kennedy and Dr. Luca Faconti’s in King’s College London.

References

Alam K, Meidell RS, and Spady DK. 2001. Effect of up-regulating individual steps in the reverse cholesterol transport pathway on reverse cholesterol transport in normolipidemic mice. J Biol Chem 276:15641-15649. 10.1074/jbc.M010230200
Bachorik PS, Lovejoy KL, Carroll MD, and Johnson CL. 1997. Apolipoprotein B and AI distributions in the United States, 1988–1991: results of the National Health and Nutrition Examination Survey III (NHANES III). 43:2364-2378.
Bae U, Shim J, Lee H, and Shin J. 2013. Serum carcinoembryonic antigen level is associated with arterial stiffness in healthy Korean adult. 415:286-289.
Berlanga A, Guijijurado E, Porras JA, and Auguet T. 2014. Molecular pathways in non-alcoholic fatty liver disease. 7:221-239.
Byrne CD, Olufadi R, Bruce KD, Cagampang FR, and Ahmed MH. 2009. Metabolic disturbances in non-alcoholic fatty liver disease. 116:539-564.
Byrne CD, and Targher G. 2015. NAFLD: A multisystem disease. 62.
Caldas CAM, Borba EF, Bortolotto LA, Medeiros DM, Bonfa E, and Goncalves CR. 2013. Increased arterial stiffness assessed by pulse wave velocity in Behçet’s disease and its association with the lipid profile. 27:454-459.

Castellani LW, and Lusis AJ. 2001. ApoA-II Versus ApoA-I Two for One Is Not Always a Good Deal. 21:1870-1872.

Choe YG, Jin W, Cho YK, Chung WG, Kim HJ, Jeon WK, and Kim BI. 2013. Apolipoprotein B/AI ratio is independently associated with non-alcoholic fatty liver disease in nondiabetic subjects. 28:678-683.

Cohen JC, Horton JD, and Hobbs HH. 2011. Human Fatty Liver Disease: Old Questions and New Insights. 332:1519-1523.

Csaszar A, Romics L, Karadi I, Tresch J, and Hansjurgen M. 1991. [Distribution of apolipoprotein A I and B in the blood according to age and gender, as well as their relation to blood cholesterol levels in the Hungarian blood donor population]. 132:1795.

De Alwis NMW, and Day CP. 2008. Non-alcoholic fatty liver disease: The mist gradually clears 48.

De Zeng M, Fan JG, Lu LG, Li Y, Chen C, Wang BY, and Mao YM. 2008. Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases. 9:108-112.

Deloach S, and Townsend RR. 2008. Vascular Stiffness: Its Measurement and Significance for Epidemiologic and Outcome Studies. 3:184-192.

Fan Y, Wei F, Zhou Y, and Zhang H. 2016. Association of non-alcoholic fatty liver disease with impaired endothelial function by flow - mediated dilation: A meta - analysis. 46.

Fok H, and Cruickshank JK. 2015. Future Treatment of Hypertension: Shifting the Focus from Blood Pressure Lowering to Arterial Stiffness Modulation? 17:67-67.

Francque S, Der Graaff DV, and Kwanten WJ. 2016. Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications. 65:425-443.

Gordon SM, Davidson WS, Urbina EM, Dolan LM, Heink A, Zang H, Lu LJ, and Shah AS. 2013. The Effects of Type 2 Diabetes on Lipoprotein Composition and Arterial Stiffness in Male Youth. 62:2958-2967.

Iannaccone R, Piacentini F, Murakami T, Paradis V, Belghiti J, Hori M, Kim T, Durand F, Wakasa K, and Monden M. 2007. Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease : Helical CT and MR imaging findings with clinical-pathologic comparison. 243:422-430.

Janner J, Godtfredsen NS, Ladelund S, Vestbo J, and Prescott E. 2010. Aortic augmentation index: reference values in a large unselected population by means of the SphygmoCor device. 23:180-185.

Jungner I, Marcovina SM, Walldius G, Holme I, Kolar W, and Steiner E. 1998. Apolipoprotein B and A-I values in 147576 Swedish males and females, standardized according to the World Health Organization-International Federation of Clinical Chemistry First International Reference Materials. Clin Chem 44:1641-1649.

Kelly RP, Hayward CS, Avolio A, and Orourke MF. 1989. Noninvasive determination of age-related changes in the human arterial pulse. 80:1652-1659.

Kim JY, Park JB, Kim DS, Kim KS, Jeong JW, Park JC, Oh BH, and Chung N. 2014. Gender Difference in Arterial Stiffness in a Multicenter Cross-Sectional Study: The Korean Arterial Aging Study (KAAS). Pulse (Basel) 2:11-17. 10.1159/000365267

Lu Y, Lu M, Dai H, Yang P, Smithgagen J, Miao R, Zhong H, Chen R, Liu X, and Huang Z. 2015. Lifestyle and Risk of Hypertension: Follow-Up of a Young Pre-Hypertensive Cohort. 12:605-612.

Ozturk K, Uygun A, Guler AK, Demirci H, Ozdemir C, Cakir M, Sakin YS, Turker T, Sari S, and Demirbas S. 2015. Nonalcoholic fatty liver disease is an independent risk factor for atherosclerosis in young adult men. 240:380-386.
Rossi P, Frances Y, Kingwell BA, and Ahimastos AA. 2011. Gender differences in artery wall biomechanical properties throughout life. 29:1023-1033.

Segers P, Rietzschel E, De Buyzere M, Vermeersch S, De Bacquier D, Van Bortel LM, De Backer G, Gillebert TC, and Verdonck P. 2007. Noninvasive (Input) Impedance, Pulse Wave Velocity, and Wave Reflection in Healthy Middle-Aged Men and Women. 49:1248-1255.

Smith JD. 2010. Dysfunctional HDL as a Diagnostic and Therapeutic Target. 30:151-155.

Sorokin A, and Kotani K. 2015. Lipoprotein(a) and Arterial Stiffness Parameters. Pulse (Basel) 3:148-152. 10.1159/000438733

Timmins JM, Lee JY, Boudyguina E, Kluckman KD, Brunham LR, Mulya A, Gebre AK, Coutinho JM, Colvin PL, Smith TL, Hayden MR, Maeda N, and Parks JS. 2005. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest 115:1333-1342. 10.1172/jci23915

Valles V, Aguilarsalinas CA, Rez FJG, Rojas R, Franco A, Olaiz G, Rull JA, and Sepulveda J. 2002. Apolipoprotein B and A-I distribution in Mexican urban adults: Results of a nationwide survey. 51:560-568.

Vlachopoulos C, Manesis EK, Baou K, Papaheodoridis GV, Koskinas J, Tiniakos D, Aznaouridis K, Archimandritis AJ, and Stefanadis C. 2010. Increased arterial stiffness and impaired endothelial function in nonalcoholic Fatty liver disease: a pilot study. 23:1183-1189.

Wong VW. 2013. Nonalcoholic fatty liver disease in Asia: A story of growth. 28:18-23.

Yanai H, Katsuyama H, Hamasaki H, Abe S, Tada N, and Sako A. 2015. Effects of Dietary Fat Intake on HDL Metabolism. 7:145-149.

Yancey PG, Bortnick AE, Kellner-Weibel G, de la Llera-Moya M, Phillips MC, and Rothblat GH. 2003. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 23:712-719. 10.1161/01.ATV.0000075752.97137.Dd

Zeng Q, Dong SY, Wang M, Wang F, Li JM, and Zhao X. 2016. Cardiac autonomic neuropathy risk estimated by sudomotor function and arterial stiffness in Chinese subjects. 30:720-725.

Zhao XQ, Hatsukami TS, Hippe DS, Sun J, Baliu N, Isquith D, Crouse JR, Anderson TJ, Huston JL, and Polissar NL. 2014. Clinical Factors Associated With High-Risk Carotid Plaque Features as Assessed by Magnetic Resonance Imaging in Patients With Established Vascular Disease (from the AIM-HIGH Study). 114:1412-1419.
**Table 1** Characteristics of the study participants, by gender

Notes: Note: Values for categorical variables are presented as number (percentage); Values for continuous variables are presented as mean ± SD.
| Variable                  | Total (mean±SD) | Male (mean±SD) | Female (mean±SD) | P value  |
|---------------------------|-----------------|----------------|-----------------|----------|
|                           | N=2295          | N=1306         | N=989           |          |
| Age (y)                   | 48.47 ± 10.22   | 47.76 ± 9.92   | 49.4 ± 9.33     | 0.0001   |
| BMI                       | 24.80 ± 3.3     | 25.57 ± 3.14   | 23.79 ± 3.24    | <0.001   |
| SBP (mmHg)                | 124.65 ± 16.54  | 126.54 ± 15.09 | 122.13 ± 17.98  | <0.001   |
| DBP (mmHg)                | 78.13 ± 11.35   | 80.88 ± 11.24  | 74.5 ± 10.45    | <0.001   |
| Educational attainment (%)|                 |                |                 |          |
| < College graduation      | 365 (15.9%)     | 275 (21.1%)    | 90 (9.1%)       |          |
| College graduation        | 1481 (64.5%)    | 955 (73.1%)    | 526 (53.2%)     | <0.001   |
| > College graduation      | 449 (19.6%)     | 76 (5.8%)      | 373 (37.7%)     |          |
| Physical Activity (%)     |                 |                |                 |          |
| Never                     | 251 (10.9%)     | 161 (12.3%)    | 90 (9.1%)       |          |
| Occasionally              | 560 (24.4%)     | 304 (23.3%)    | 256 (25.9%)     |          |
| Frequently                | 1484 (64.7%)    | 841 (64.4%)    | 643 (65.0%)     | 0.04     |
| Smoking Status (%)        |                 |                |                 |          |
| Quit                      | 101 (4.4%)      | 93 (7.1%)      | 8 (0.8%)        |          |
| Never                     | 1423 (62.0%)    | 548 (42.0%)    | 875 (88.5%)     |          |
| Occasionally              | 207 (9.0%)      | 170 (13.0%)    | 37 (3.7%)       | <0.001   |
| Frequently                | 564 (24.6%)     | 495 (37.9%)    | 69 (7.0%)       |          |
| History of Hypertension (%)|                 |                |                 |          |
| HDL (mmol/L)              | 1.58 ± 0.4      | 1.43 ± 0.35    | 1.77 ± 0.39     | <0.001   |
| LDL (mmol/L)              | 3.00 ± 0.88     | 3.01 ± 0.88    | 2.98 ± 0.89     | 0.54     |
| ApoA1 (g/L)               | 1.51 ± 0.28     | 1.43 ± 0.26    | 1.62 ± 0.27     |          |
| Right baPWV (cm/s)        | 1388.01 ± 278.2 | 1412.51 ± 261.31 | 1355.66 ± 296.09 |          |
| Left baPWV (cm/s)         | 1390.95 ± 277.03| 1413.07 ± 257.73 | 1361.72 ± 298.24 |          |
| baPWV (cm/s)              | 1389.48 ± 273.5 | 1412.79 ± 255.13 | 1358.69 ± 293.34 | <0.001   |
| Arterial Stiffness        | 953 (41.56%)    | 585 (44.79%)   | 350 (35.39%)    | <0.001   |
Table 2 (on next page)

Odd ratios for the Incidence of arterial stiffness, by gender

Model 1: logistic regression for the Incidence of arterial stiffness and ApoA1, and adjusted for age, gender and BMI for total population; age and BMI for Male and Female population;

Model 2: Model 1 and adjusted for Educational attainment, Physical activity, Smoking status and history of hypertension;

Model 3: Model 2 and adjusted for HDL LDL.

*: p<0.05; **: p<0.001
| Variable | Total |   |   | Male |   |   | Female |   |   |
|----------|-------|---|---|------|---|---|---------|---|---|
|          | N=2295|   |   | N=1306|   |   | N=989   |   |   |
|          | OR    | 95% CI | OR | 95% CI | OR | 95% CI | OR | 95% CI |
| Model 1  | 1.20  | (0.84, 1.72) | 1.88* | (1.06, 3.33) | 1.36 | (0.83, 2.22) | 1.93** | (1.22, 3.05) | 0.57 | (0.31, 1.03) |
| Model 2  | 1.69* | (1.08, 2.66) | 1.89 | (0.95, 3.77) | 1.80 | (0.97, 3.37) | 2.80** | (1.55, 5.04) | 0.74 | (0.35, 1.58) |
| Model 3  | 4.46**| (1.85, 10.77) | 4.18* | (1.16, 15.1) | 4.70* | (1.36, 16.23) | 3.96* | (1.29, 12.30) | 2.92 | (0.63, 13.59) |
Table 3 (on next page)

Linear Regression between Apoa1 and baPWV in male patients

Model1: Linear regression for baPWV and ApoA1;

Model2: Model 1 and adjusted for age, BMI Educational attainment, Physical activity, Smoking status and history of hypertension;

Model3: Model 2 and adjusted for HDL LDL.
| Variable | Coefficient | 95%CI     | P value |
|----------|-------------|-----------|---------|
| Model 1  | 160.02      | 107.37, 212.66 | <0.001 |
| Model 2  | 139.84      | 83.97, 195.68  | <0.001 |
| Model 3  | 156.42      | 49.34, 263.50  | 0.004  |
Figure 1

Relationship between ApoA1 as a continuous variable and risk of the incidence of arterial stiffness in male patients

Relationship between ApoA1 as a continuous variable and risk of the incidence of arterial stiffness in male patients. Results were obtained by multivariable logistic regression with restricted splines including ApoA1. ApoA1 levels were categorized into 0.5 g/L increment from <1 to >3 g/L and were adjusted for age, gender, BMI, education, physical activity, smoking, history of hypertension, HDL and LDL level. The upper and lower 95% CIs are denoted by dotted line.
